Monday, October 29, 2018 @ 8:30am Eastern Time
Toll Free: 888-220-8451
Israel Investors: 1809 212 909
International: 323-794-2588
Conference ID: 5255627
Webcast: https://goo.gl/5YVAsj
Replays, available through November 12, 2018
Toll Free: 844-512-2921
International: 412-317-6671
Conference ID: 5255627
About BrainStorm Cell Therapeutics Inc.
BrainStorm Cell Therapeutics Inc. is a biotechnology company engaged in the development of first-of-its-kind adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases.
The Company has developed the NurOwn® technology into a commercially viable product. NurOwn has been already administered to over 70 patients with ALS in clinical trials conducted in the United States and in Israel. In a randomized, double blind, placebo-controlled clinical trial conducted in the U.S., a clinically meaningful benefit was demonstrated by higher response to NurOwn compared with placebo. The Company is currently conducting a Phase 3 double blind, placebo-controlled clinical trial at multiple clinical sites throughout the US. For more information, visit the company's website at www.brainstorm-cell.com.
CONTACTS
Media:
Uri Yablonka
Chief Business Officer
BrainStorm Cell Therapeutics Inc.
Phone: (646) 666-3188
uri@brainstorm-cell.com
Investors:
Michael Rice
LifeSci Advisors, LLC
Phone: 646-597-6979
mrice@lifesciadvisors.com
BrainStorm Cell Therapeutics Inc.